Telaprevir-based triple therapy for re-treatment Chronic HCV patients with Genotype 1, including the Null-Response: A single center experience from Turkey

Abstract

Background: Telaprevir with peginterferon/ribavirin (TVR/PR) leads to significantly higher sustained virological response (SVR) rates with partial response or relapse after prior treatment with peginterferon alpha (PegIFN)/ribavirin (RBV) in patients infected with hepatitis C. We studied the efficacy of TVR/PR in patients with prior treatment failure, including those with a null response (<2 Log10 decline in HCV RNA), to peginterferon/ribavirin).